|
Dr. Yelena Usmanova is involved in numerous research trials related to advances in the treatment of Multiple Sclerosis.
WA21092 (“Opera”)
Study Overview
A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab In comparison to Interferon Beta-1a (Rebif ®) in patients with relapsing multiple sclerosis
Study Duration = approx. 96 weeks
Phase – 3
Principle Investigator
Gary Birnbaum, MD
Sponsor
F. Hoffmann-La Roche Ltd/ Genetech Inc.
Research Contact
If interested please contact Nicole Goese (Clinical Research Coordinator) at 763-302-4072.
OMS112831(“Mirror”)
Study Overview
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the MRI efficacy and safety of six months’ administration of of atumumab in subjects with relapsing-remitting multiple sclerosis (RRMS)
Study Duration = 24 weeks (plus up to 6 weeks screen)
Phase - 2
Principle Investigator
Gary Birnbaum, MD
Sponsor
GlaxoSmithKline
Research Contact
If interested please contact Nicole Goese (Clinical Research Coordinator) at 763-302-4072.
The EPOC Study – DUS01 (Closed)
What is the EPOC study?
EPOC is a 6-month clinical research study involving patients who are currently being treated for relapsing forms of MS. The main purpose of this study is to learn about patient satisfaction, safety and tolerability with Fingolimod compared to other approved MS drugs. About 1,000 patients with relapsing forms of MS will join this study at about 175 medical centers in the United States.
What happens during the study?
During this 6-month study, you will receive treatment of either the study drug (Fingolimod) or another drug that is currently being used to treat patients diagnosed with relapsing forms of MS. Whether you receive the study drug or a currently available therapy is decided by chance (like tossing a coin). Three out of four patients will receive the study drug.
Study Appointments
After the study screening, you will be scheduled for five office visits during the 24-week (6-month) study. Most visits will take about an hour. Some visits may require extra time. If you are chosen to receive Fingolimod, you will need to stay in the study doctor’s office for 7-8 hours on the second visit, which is when you take your first dose.
Principal Investigator
Jonathan Calkwood, M.D.
Clinical Trial Sponsor
Novartis
Follow this link to find other location listings and/or take an online screening questionnaire.
109MS201 (Closed)
An Open-Label, Multicenter Study in Subjects with Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Purpose of study
To evaluate the safety and determine if the investigational drug BG0012, when taken in combination with another prescribed MS therapy, improves MS symptoms. You may be eligible for this study if you have relapsing-remitting MS, have been on an MS therapy for at least one year and still have symptoms.
Principal Investigator
Jonathan Calkwood, M.D.
Clinical Trial Sponsor
Biogen
|
